Galecto Biotech

Fibrosis / Lung diseases


HBM contact: Dr Ivo Staijen, Dr Chandra P. Leo

Company status: public

Galecto develops novel drugs targeting a group of proteins called galectins (or galactoside-binding lectins). These drugs have applications in the treatment of fibrosis, inflammation, and other serious conditions. Galecto's lead asset TD139 is a potent and selective inhalable inhibitor of galectin-3. TD139 is in advanced development for idiopathic pulmonary fibrosis (IPF), a chronic, progressive and ultimately deadly lung disease. Galecto is located in Copenhagen, Denmark.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171